Pharma Pulse: Novartis Acquires Avidity and Trump's Tariff Threat
This episode of Pharma Pulse discusses Novartis' $12 billion acquisition of Avidity Biosciences and President Trump's proposed 10% tariff increase on Canadian imports.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast covering patient access, supply chain/logistics, data & tech, and healthcare innovation.
Novartis' Acquisition and Trade Tensions
Novartis' $12 billion acquisition of Avidity Biosciences expands its RNA therapeutics portfolio. Meanwhile, President Trump's proposed tariff hike on Canadian imports could disrupt pharma supply chains.
From billion-dollar biotech deals to potential tariff shocks, these developments illustrate the critical interplay between science, business, and policy shaping pharma's global landscape.
For more insights, visit pharmaceuticalcommerce.com.
Author's summary: Novartis buys Avidity for $12B amidst trade tensions.
More News
- Capitalism has no place in Islamic practices
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Gavin Newsom Says He Has 'No Interest' in Appearing on Joe Rogan's Podcast: 'I'm Moving On' | Video
- SKIMS’ chilling vision of the perfect female body
- Mnangagwa delivers part of State of the Nation address in darkness after power outage – Nehanda Radio
- Lauri Markkanen first Jazz player to score 50 points since Karl Malone in win over Suns
- Reimagining Nail Care: Turning Self-Care Into an Engine for Equity
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- Remains unearthed in Schenectady buried at local cemetery
- ‘Everyone is talking about’ co-located solar and storage PPA in Europe